Breast lumps classification
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shadan Mehraban, M.D.[2]
Overview
Overview
Breast lumps may be classified according to epithelial hyperplasia into 3 subtypes: non-proliferative, proliferative disease and proliferative disease without atypia. Breast lumps may be classified into 3 sub-types based on histological regions: lobular region, ductal region, different origins.
Classification
Classification
Classification of breast lumps based on epithelial hyperplasia:[1][2][3]
- Approximately 65% of all benign breast disease considered as non-proliferative (NP) with relative cancer risk of 1.2 – 1.4 times:
- Cyst (most common)[4]
- Fibrosis
- Fibroadenoma (simple)
- Columnar alteration (Simple)
- Apocrine metaplasia (simple)
- Mild ductal hyperplasia
- Approximately 30% of total are classified as proliferative disease (PD) with relative cancer risk of 1.7 – 2.1 times:[5]
- Usual ductal hyperplasia
- Sclerosing adenosis
- Columnar hyperplasia
- Papilloma
- Radical scar
- Approximately 5% to 8% of the rest are regarded as PD with atypia and relative cancer risk more than 4 times:[6]
- Atypical lobar hyperplasia
- Lobular carcinoma in situ
- Atypical ductal hyperplasia
- Unclear risk
Classification of benign breast lesion according to histological region:[7]
- Terminal and lobular ducts
- Acinar distention
- Intralobular connective tissue proliferation
- Epithelial changes in terminal duct lobular units (TDLU)
- Apocrine metaplasia
- Ductal and lobular hyperplasia, usual and typical
- Papillomatosis
- Intracystic papilloma
- Ductal system
- Lesion of different origin
- Fatty tissue lesion
- Lipoma
- Liponecrosis
- Fibrous tissue lesions
- Vascular origin
- Inflammatory origin
- Mastitis/abscess
- Tuberculosis and sarcoidosis
- Foreign body granuloma and siliconoma
- Lymph node origin
- Fatty tissue lesion
References
References
- ↑ Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K; et al. (2005). “Benign breast disease and the risk of breast cancer”. N Engl J Med. 353 (3): 229–37. doi:10.1056/NEJMoa044383. PMID 16034008.
- ↑ London SJ, Connolly JL, Schnitt SJ, Colditz GA (1992). “A prospective study of benign breast disease and the risk of breast cancer”. JAMA. 267 (7): 941–4. PMID 1734106.
- ↑ Dupont WD, Page DL (1985). “Risk factors for breast cancer in women with proliferative breast disease”. N Engl J Med. 312 (3): 146–51. doi:10.1056/NEJM198501173120303. PMID 3965932.
- ↑ Love SM, Gelman RS, Silen W (1982). “Sounding board. Fibrocystic “disease” of the breast–a nondisease?”. N Engl J Med. 307 (16): 1010–4. doi:10.1056/NEJM198210143071611. PMID 7110289.
- ↑ Dupont WD, Page DL (1985). “Risk factors for breast cancer in women with proliferative breast disease”. N Engl J Med. 312 (3): 146–51. doi:10.1056/NEJM198501173120303. PMID 3965932.
- ↑ Page DL, Dupont WD, Rogers LW, Landenberger M (1982). “Intraductal carcinoma of the breast: follow-up after biopsy only”. Cancer. 49 (4): 751–8. PMID 6275978.
- ↑ Lanyi, M (2003). Mammography : diagnosis and pathological analysis. Berlin New York: Springer-Verlag. ISBN 9783540441137.
- ↑ Lai EC, Chan WC, Ma TK, Tang AP, Poon CS, Leong HT (2005). “The role of conservative treatment in idiopathic granulomatous mastitis”. Breast J. 11 (6): 454–6. doi:10.1111/j.1075-122X.2005.00127.x. PMID 16297091.
- ↑ Kudva YC, Reynolds C, O’Brien T, Powell C, Oberg AL, Crotty TB (2002). ““Diabetic mastopathy,” or sclerosing lymphocytic lobulitis, is strongly associated with type 1 diabetes”. Diabetes Care. 25 (1): 121–6. PMID 11772912.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH